Literature DB >> 8270245

Echo-guided percutaneous ethanol injection in small hepatocellular carcinoma: personal experience.

L Solmi1, R Muratori, F Bertoni, L Gandolfi.   

Abstract

We performed echo-guided percutaneous ethanol injection of the lesion in 26 cirrhotic patients with 33 hepatocellular carcinomas measuring 3 cm in diameter or less. Post-treatment lesions had disappeared in 4 patients, while in the remaining 22 patients the echo pattern of the lesion had changed and biopsies were negative. Fifteen patients (follow-up 11-30 months) remain disease-free, while recurrence occurred between 3 and 36 months in 7 cases. Percutaneous ethanol injection was successfully repeated in 4 cases; 5 patients died, 1 of HCC, 2 of esophageal variceal bleeding, and 2 of liver failure; 3 of the last four patients had Child's C disease. Percutaneous ethanol injection is a valuable treatment for hepatocellular carcinomas measuring not more than 3 cm. It has yet to be established how far this treatment influences the survival rates of patients and the natural course of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8270245

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

1.  Therapeutic effectiveness of echo-guided percutaneous radiofrequency ablation therapy with a LeVeen needle electrode in hepatocellular carcinoma.

Authors:  Luigi Solmi; Giovanni Nigro; Enrico Roda
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

2.  Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection.

Authors:  Noriyuki Miyamoto; Kazuhide Hiramatsu; Kazuhiko Tsuchiya; Yukihiko Sato; Satoshi Terae; Hiroki Shirato
Journal:  Jpn J Radiol       Date:  2009-06-06       Impact factor: 2.374

3.  Intralesional ethanol in the treatment of unresectable liver cancer.

Authors:  T Livraghi; S Lazzaroni; F Meloni; G Torzilli; C Vettori
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.